Histone Deacetylase Inhibitors Market Size & Share, by Classification (Class I HDACs, Class II HDACs, Class III HDACs); Application (Oncology, Neurology); Drugs (Vorinostat, Romidepsin, Belinostat, Panabinostat); End-User (Hospitals, Homecare, Specialty Clinics); Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy); Route of Administration (Oral HDAC Inhibitors, Parenteral HDAC Inhibitors) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5349
  • Published Date: Oct 30, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Histone Deacetylase Inhibitors Market size is poised to reach USD 3 Billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of histone deacetylase inhibitors was USD 1.20 Billion. The reason behind the growth is impelled by the rising cases of cancer across the globe. HDAC inhibitors that allow acetylation equilibrium to be restored may be helpful in the treatment of cancer as they are similar to other anti-cancer medications, and are widely being used as a single agent or in combination with other chemotherapeutics in the treatment of tumors by promoting tumor cell death. By 2040, there will be more than 25 million new instances of cancer annually throughout the world.

The growing research & development activities for the development of advanced drugs are believed to fuel the growth of histone deacetylase inhibitors market. The creation of HDAC inhibitors has become a key tactic in the design of novel therapies that are being developed as a new, focused class of anticancer medications and several HDAC inhibitors (HDAC) have already been approved by the Food and Drug Administration (FDA) and are now being tested in clinical settings for a variety of cancers.

Get more information on this report: Request Free Sample PDF

Histone Deacetylase Inhibitors Market: Growth Drivers and Challenges

Growth Drivers

  • Rising Incidence of Neurodegenerative Disorders – In addition to improving neurological function, HDAC inhibitors also have anti-inflammatory, neurotrophic, and neuroprotective properties as a result it has drawn a lot of attention for Huntington's disease, which is a polyglutamine illness, and other neurological disorders. For instance, more than 10% of the global population today suffers from neurological illnesses, which are the most common cause of physical and cognitive disability.
  • Spiking Cases of Multiple Myeloma- For the treatment of multiple myeloma, HDAC inhibitors have received clinical approval as they have demonstrated potential efficacy in the treatment of relapsed multiple myeloma.
  • Growing Popularity of Target Therapies- Histone deacetylase inhibitors are novel targeted therapies that can target the expression of HDACs, which makes them attractive therapeutic targets.
  • Increase in Number of People with Cachexia- In advanced stages of many chronic diseases, such as chronic heart failure, cachexia frequently appears and HDAC inhibitor is one way to treat cachexia in cancer-bearing mammals.
  • Development of Combination Therapies-  HDACi have shown promising anticancer effects when combined with conventional chemotherapeutic medicines since by increasing histone acetylation and gene expression, the susceptibility of cancer cells to chemotherapy increases.
  • Urothelial Carcinoma Therapy- Promising anti-cancer medications known as histone deacetylase inhibitors (HDACi) may also be used for urothelial carcinoma treatment as it enhances expression of the transgene.
  • Increasing Prevalence of Rare Diseases- HDAC inhibitors (HDACi), have demonstrated promise in the treatment of several rare illnesses such as (RTT) Rett Syndrome an uncommon neurodevelopmental disease that is mostly attributed to the lack of functional mutations.


  • Adverse Effects of HDAC (Histone Deacetylase) Inhibitors - Some side effects of the inhibitors (grades III and IV) include a variety of serious and/or severe side effects that are agent- and class-specific, including myelosuppression, diarrhea, as well as the most concerning side effect, which includes ventricular arrhythmia, has been cardiac toxicity all of which are recoverable with drug withdrawal.
  • Limited Reimbursement Policies in Developing Regions
  • High Cost of Research & Development Activities

Histone Deacetylase Inhibitors Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 1.20 Billion

Forecast Year Market Size (2036)

~ USD 3 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Histone Deacetylase Inhibitors Segmentation

Route of Administration (Oral HDAC Inhibitors, Parenteral HDAC Inhibitors)

The oral histone deacetylase inhibitors market is estimated to hold 55% of the revenue share during the forecast period owing to the huge availability of orally HDAC inhibitors. The epigenetic agents known as histone deacetylase inhibitors (HDAC inhibitors, HDACi, HDIs) are pharmacological substances that induce the cell cycle gene p21 to be upregulated and are in recent development in the field of drug research.

Oral HDAC (Histone Deacetylase) inhibitors are a type of medication that can have several potential benefits, including the ability to regulate gene expression and offer a broad spectrum of anticancer action.

The oral HDAC inhibitor valproic acid (VPA) inhibits HDAC which suppresses the cell growth of small-cell lung cancer. Additionally, TYA-018 is a very effective and specific HDAC6 inhibitor that can be used orally that improve energetics in mice by boosting the expression of genes. Furthermore, The HDAC inhibitor panobinostat is a powerful and non-selective oral agent that increases HIV-1 expression in cells that are latently infected and may be employed for the investigation of refractory or relapsed multiple myeloma. Besides this, the parenteral HDAC inhibitors segment is anticipated to gain significant share during the forecast timeframe.

Application (Oncology, Neurology)

Histone deacetylase inhibitors market from the oncology electronics segment is set to garner a notable share shortly. HDAC inhibitors hold a promising avenue in the field of oncology as ongoing research and clinical trials are continually exploring their effectiveness in treating different types of cancers, contributing to the rise in demand. Moreover, HDAC, a novel class of anticancer therapeutic targets, has received extensive research since it causes tumor cell death with all of the morphological and cellular hallmarks of apoptosis and can also reverse the aberrant acetylation state of proteins present in cancer cells.

End-User (Hospitals, Homecare, Specialty Clinics)

The hospitals segment in the histone deacetylase inhibitors market is poised to gain a robust revenue share by the year 2036. Hospitals are increasingly requesting HDAC (Histone Deacetylase) inhibitors as a result of their ability to treat a variety of malignancies since some cancer treatments still include care as a crucial component, and cancer surgery outcomes are better in hospitals with greater infrastructure and resources.

Our in-depth analysis of the global histone deacetylase inhibitors market includes the following segments:


  • Class I HDACs
  • Class II HDACs
  •  Class III HDACs


  • Oncology
  • Neurology


  • Vorinostat
  • Romidepsin
  •  Belinostat
  •  Panabinostat


  • Hospitals
  • Homecare
  • Specialty Clinics

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  •  Retail Pharmacy

Route of Administration

  • Oral HDAC Inhibitors
  •  Parenteral HDAC Inhibitors

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Histone Deacetylase Inhibitors Industry - Regional Synopsis

North American Market Forecast

Histone deacetylase inhibitors market in North America is predicted to account for the largest share of 35% by 2036 impelled by rising investment in healthcare. This has led to a rise in research & development capacities for the development of advanced drugs including HDAC inhibitors in the region. According to estimates, spending on healthcare in the United States in 2021 was more than USD 4 trillion, or around USD 12,800 per person.

APAC Market Statistics

The APAC histone deacetylase inhibitors market is estimated to be the second largest, during the forecast timeframe led by rising governmental initiatives to create cancer awareness. For instance, The National Cancer Grid (NCG) was established to unite cancer treatment facilities across India to establish uniform patient care standards for cancer prevention, diagnosis, and treatment, and offer specialized oncology training and education to ensure that patients from all regions of the nation receive the same high-quality care without having to travel far or worry about their ability to pay for treatment.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Histone Deacetylase Inhibitors Market

    • Acrotech Biopharma Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bristol Myers Squibb Co.
    • Celleron Therapeutics Ltd.
    • Novartis AG
    • Midatech Pharma PLC
    • Syndax Pharmaceuticals Inc.
    • Viracta Therapeutics Inc.
    • Xynomic Pharmaceuticals (Nanjing) Co. Ltd.
    • Cetya Therapeutics Inc.

In the News

  • Bristol Myers Squibb Co. acquired Mirati Therapeutics, Inc. to expand its commercial portfolio by including KRAZATI, a critical drug for the treatment of adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). Furthermore, the business aims to strengthen its pipeline of oncology products and are excellent candidate for both single-agent development and combination approaches to guarantee that patients around the world may benefit from Mirati's array of cutting-edge medications.
  • Celleron Therapeutics Ltd. partnered with Roche to receive rights to the clinical development, and commercialization of cancer drugs, Emactuzumab, an investigational monoclonal antibody that targets and reduces macrophages in tumor tissue.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5349
  • Published Date: Oct 30, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising cases of cancer across the globe and the growing research & development activities for the development of advanced drugs are the major factors driving the growth of the market.

The market size of HDAC (Histone Deacetylase) Inhibitors is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024 – 2036.

The major players in the market are Novartis AG, Midatech Pharma PLC, REGENACY PHARMACEUTICALS, INC., Syndax Pharmaceuticals Inc., Viracta Therapeutics Inc., Xynomic Pharmaceuticals (Nanjing) Co. Ltd., Cetya Therapeutics Inc., Tokyo Chemical Industry Co. Ltd., AstraZeneca Plc.

The oral HDAC inhibitors segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Histone Deacetylase Inhibitors Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying